- Home
- PRG vs AKRO Comparison
PRG vs AKRO Comparison
Compare PRG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- AKRO
- Stock Information
- Founded
- PRG 2020
- AKRO 2017
- Country
- PRG United States
- AKRO United States
- Employees
- PRG N/A
- AKRO N/A
- Industry
- PRG Diversified Commercial Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- AKRO Health Care
- Exchange
- PRG Nasdaq
- AKRO Nasdaq
- Market Cap
- PRG 1.8B
- AKRO 2.0B
- IPO Year
- PRG N/A
- AKRO 2019
- Fundamental
- Price
- PRG $42.29
- AKRO $28.08
- Analyst Decision
- PRG Buy
- AKRO Strong Buy
- Analyst Count
- PRG 6
- AKRO 8
- Target Price
- PRG $53.00
- AKRO $46.83
- AVG Volume (30 Days)
- PRG 366.4K
- AKRO 594.3K
- Earning Date
- PRG 02-19-2025
- AKRO 02-27-2025
- Dividend Yield
- PRG 1.14%
- AKRO N/A
- EPS Growth
- PRG 8.67
- AKRO N/A
- EPS
- PRG 3.58
- AKRO N/A
- Revenue
- PRG $2,417,577,000.00
- AKRO N/A
- Revenue This Year
- PRG $2.85
- AKRO N/A
- Revenue Next Year
- PRG $6.70
- AKRO N/A
- P/E Ratio
- PRG $11.80
- AKRO N/A
- Revenue Growth
- PRG N/A
- AKRO N/A
- 52 Week Low
- PRG $27.84
- AKRO $15.32
- 52 Week High
- PRG $50.28
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- PRG 36.80
- AKRO 41.87
- Support Level
- PRG $41.00
- AKRO $27.45
- Resistance Level
- PRG $43.22
- AKRO $28.76
- Average True Range (ATR)
- PRG 1.48
- AKRO 1.49
- MACD
- PRG -0.14
- AKRO -0.12
- Stochastic Oscillator
- PRG 16.60
- AKRO 17.98
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The Company has two reportable segments: (i) Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and (ii) Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the progressive leasing segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.